Overview
This study aims to exploratorily evaluate the extent of motor and cognitive changes, as well as the safety, resulting from approximately 10 weeks of whole-body photobiomodulation (PBM) therapy (about three sessions per week, once daily, 20 minutes per session) in patients with Parkinson's disease.
Eligibility
Inclusion Criteria:
- Individuals diagnosed with Parkinson's disease at Hoehn and Yahr stages 1-3 based on medical history and examination
- Adults aged 40 years or older
- Individuals able to walk independently
Exclusion Criteria:
- Individuals with severe cognitive impairment (Korean Mini-Mental State Examination \[K-MMSE\] score ≤ 9) making it difficult to understand and perform tasks
- Patients with dementia other than Parkinson's disease dementia
- Individuals with implanted medical or other electronic devices
- Individuals with severe neuropsychiatric disorders
- Individuals treated for alcohol dependence within 6 months prior to screening
- Individuals with a history of suicide attempts
- Individuals with a history of seizures
- Individuals experiencing dyspnea while sitting at rest
- Individuals with visual impairment preventing them from reading ordinary text even with corrective lenses
- Individuals with hearing impairment preventing them from understanding conversation even with a hearing aid
- Individuals who have participated in two or more clinical trials in the same year or in another clinical trial within the past 6 months
- Women and men of childbearing potential who are planning pregnancy during the trial or who do not agree to use appropriate contraceptive methods
- Pregnant or breastfeeding women
- Individuals deemed medically inappropriate for participation by the principal investigator or study staff based on clinically significant findings not otherwise specified above